Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 vs Paclitaxel in Advanced Gastric Cancer (SHINE)
NCT01457846Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2011
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial of fexagratinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by AstraZeneca. Primary endpoint: Median Progression Free Survival. Started Nov 2011; status: terminated.
02
Drugs
fexagratinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01457846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01457846.